enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 60,300 shares, a decline of 31.9% from the February 13th total of 88,500 shares. Based on an average daily volume of 131,100 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.3% of the company’s stock are short sold.

Hedge Funds Weigh In On enGene

A number of institutional investors and hedge funds have recently modified their holdings of ENGN. Franklin Resources Inc. raised its position in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares during the period. Point72 Asset Management L.P. increased its stake in enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares during the period. Vontobel Holding Ltd. bought a new stake in shares of enGene during the fourth quarter worth $69,000. Wolverine Asset Management LLC purchased a new stake in shares of enGene during the third quarter valued at $37,000. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after purchasing an additional 2,080 shares during the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on ENGN shares. Citizens Jmp raised enGene to a “strong-buy” rating in a research report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of enGene in a research report on Tuesday, March 11th. Piper Sandler initiated coverage on enGene in a report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price target on the stock. Raymond James began coverage on shares of enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price for the company. Finally, Morgan Stanley lowered their target price on enGene from $37.00 to $34.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $25.22.

enGene Price Performance

Shares of ENGN traded down $0.19 during mid-day trading on Monday, hitting $5.21. 17,877 shares of the stock were exchanged, compared to its average volume of 131,523. The firm has a 50-day moving average of $6.51 and a two-hundred day moving average of $7.12. enGene has a 52-week low of $4.42 and a 52-week high of $18.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The company has a market cap of $265.59 million, a PE ratio of -8.98 and a beta of -0.61.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, equities analysts predict that enGene will post -1.56 earnings per share for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.